PhaseBio Pharmaceuticals to Participate in Upcoming Investor Conferences
PhaseBio Pharmaceuticals (Nasdaq: PHAS), a clinical-stage biopharmaceutical company, will participate in two virtual investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that the company will be participating in two upcoming virtual investor conferences. Details of the events are as follows:
-
Cowen 41st Annual Health Care Conference
Date: March 4, 2021
Time: 1:30 pm – 2:30 pm ET
Chief Executive Officer, Jonathan P. Mow, is scheduled to participate in a panel discussion
-
H.C. Wainwright Global Life Sciences Conference
Date: March 9, 2021
Time: On demand beginning at 7:00 am ET
Chief Executive Officer, Jonathan P. Mow, will present a company overview
Interested parties can access the live and archived webcasts of the virtual sessions on the “Events and Presentations” page of the “Investors” section of the company’s website at www.phasebio.com. The webcast replays will be available for 90 days after the conclusion of the live presentations.
About PhaseBio
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. The company’s pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including pemziviptadil, and drives both internal and partnership drug-development opportunities.
PhaseBio is located in Malvern, PA, and San Diego, CA. For more information, please visit www.phasebio.com, and follow us on Twitter @PhaseBio and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210226005652/en/